Pricing Log in Create free account

Lipocine Inc. (LPCN) vs TScan Therapeutics, Inc. (TCRX)

Lipocine Inc. and TScan Therapeutics, Inc. are both Biotechnology companies. Lipocine Inc. and TScan Therapeutics, Inc. are of similar size ($12.6M and $12.3M). TScan Therapeutics, Inc. grew revenue faster over the last twelve months: 2.15% against −13.4%. Lipocine Inc. has the higher net margin (−249.2% vs −1,655.4%) and the higher return on invested capital (0.00% vs −4,588.2%). Across the 18 metrics below, Lipocine Inc. leads on 11 and TScan Therapeutics, Inc. on 7.

Valuation

Metric LPCN TCRX Biotechnology median
P/E n/m n/m 10.60
P/S 3.46 3.29 9.40
P/B 0.61 0.34 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA 0.54 0.37 0.66
EV/Sales (1.49) (6.19) 9.02
Earnings yield (86.62%) (505.56%) (32.88%)
Free cash flow yield (78.12%) (506.23%) (23.13%)

Profitability

Metric LPCN TCRX Biotechnology median
Gross margin 100.00% 100.00% 68.51%
Operating margin (269.05%) (1,695.15%) 0.00%
Net margin (249.16%) (1,655.35%) 0.00%
Free cash flow margin (267.37%) (1,665.18%) 0.00%
Return on equity (52.86%) (95.80%) (51.96%)
Return on assets (47.52%) (50.09%) (46.06%)
Return on invested capital 0.00% (4,588.23%) 0.00%

Growth

Metric LPCN TCRX Biotechnology median
Revenue growth (TTM) (13.36%) 2.15% 6.76%
EPS growth (last fiscal year) (93,988.89%) 12.28% 29.88%
Revenue growth, 5-year CAGR 64.32% 56.92% 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric LPCN TCRX Biotechnology median
Debt to equity 0.00 0.47 0.00
Current ratio 11.36 3.37 4.97
Net debt to EBITDA 1.42 0.90 1.01

Dividend

Metric LPCN TCRX Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric LPCN TCRX Biotechnology median
Market cap 12.61m 12.32m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack